Durvalumab May Be Effective in Patients with EGFR+/ALK+ NSCLC [Clinical Trials]

PD-L1 blockade with durvalumab achieves responses in patients with EGFR⁺/ALK⁺ and EGFR^–/ALK^– NSCLC.

from Cancer via ola Kala on Inoreader https://ift.tt/2JCXLxG
via IFTTT